Baylor College of Medicine

FIVE UNSAFE SKIN CARE TRENDS TO AVOID

Retrieved on: 
Wednesday, November 1, 2023
FAAD, Nail, Science, FDA, Social media, Mouth, Dermatology, Food, Hair loss, SPF, Health, UV, Allergic contact dermatitis, Skin care, Swimming, Skin, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Laser, Baylor College of Medicine, AAD, Dermatitis, Acne, Risk, Hair, Cancer, Perspiration, UPF, Patient, Skin cancer, Clothing, Birth, Infection, Baylor University, Cosmetics, Dietary supplement, MD, Scotch

ROSEMONT, Ill. , Nov. 1, 2023 /PRNewswire/ -- Social media platforms are rife with skin care advice from a variety of sources, which can make it difficult to know how to approach the recommendations you find online. In recognition of National Healthy Skin Month this November, board-certified dermatologists are spotlighting unsafe skin care trends that they see on social media and elsewhere to help you keep your skin looking its best.

Key Points: 
  • In recognition of National Healthy Skin Month this November, board-certified dermatologists are spotlighting unsafe skin care trends that they see on social media and elsewhere to help you keep your skin looking its best.
  • While self-tanner that you apply to your skin is a safe way to look tan, nasal tanning spray is not.
  • The sun exposure increases your risk of developing skin cancer and signs of premature skin aging like wrinkles and age spots.
  • Board-certified dermatologists have the expertise and training needed to perform cosmetic procedures and advise people on how to best care for and protect their hair, skin, and nails.

PARAPRO'S THOUGHT LEADER AI: WHERE ARTIFICIAL INTELLIGENCE MEETS SCABIES EXPERTISE

Retrieved on: 
Thursday, October 26, 2023
FAAD, Institute for Creative Technologies, Michael, FDA, The Pediatric Infectious Disease Journal, Health care, Scabies, Infection, Michael E. DeBakey Veterans Affairs Medical Center in Houston, Pediatrics, Baylor College of Medicine, University, ICT, Hospital, Diagnosis, Baylor University, Creative Technology, Head, Medical device, Veterinary medicine, Dermatology, MD, FAAP

CARMEL, Ind., Oct. 26, 2023 /PRNewswire/ -- ParaPRO, a leading specialty pharmaceutical company specializing in innovative treatments for human ectoparasites, has unveiled Thought Leader AI. This cutting-edge decision support tool, developed in collaboration with the Institute for Creative Technologies (ICT) at the University of Southern California, enables healthcare practitioners to conduct lifelike consultations with top scabies specialists. From diagnosis to treatment, Thought Leader AI aims to support clinical decision-making and foster a virtual exchange of expert insights. Healthcare providers can visit www.thoughtleaderai.org to experience Thought Leader AI in action. Non-healthcare providers can contact [email protected] to receive instructions on how to access the platform.

Key Points: 
  • From diagnosis to treatment, Thought Leader AI aims to support clinical decision-making and foster a virtual exchange of expert insights.
  • Healthcare providers can visit www.thoughtleaderai.org to experience Thought Leader AI in action.
  • Thought Leader AI also informs clinicians about available treatment options, including the first and only FDA-approved 'complete cure' for scabies."
  • Thought Leader AI addresses these challenges head-on, allowing practitioners to seek real-time expert advice, gain invaluable clinical insights, and explore best practices.

Pew Funds 6 Teams to Advance Cutting-Edge Biomedical Research

Retrieved on: 
Tuesday, October 24, 2023
New York University Grossman School of Medicine, Health, Kathryn, Pennsylvania State University, Cyanobacteria, Songbird, Human, The Pew Charitable Trusts, Pathology, Livestock, Carbon, Human Development Innovation Fund, Perelman School of Medicine at the University of Pennsylvania, Research, Metabolism, Littman, Mouse, Baylor College of Medicine, Disease, Medicine, Biology, Plant, Bacteria, Animal, University, Cornell University, Massachusetts Institute of Technology, Pew, Brain, New York University, Inflammatory bowel disease, Pharmaceutical industry, Medical device, Agriculture

The Pew Charitable Trusts announced today the six pairs of researchers who will make up its 2023 class of Innovation Fund investigators.

Key Points: 
  • The Pew Charitable Trusts announced today the six pairs of researchers who will make up its 2023 class of Innovation Fund investigators.
  • These 12 acclaimed scientists—all alumni or advisors of Pew's biomedical programs in the United States and Latin America—will partner on interdisciplinary research projects exploring key questions in human biology and disease.
  • For nearly 40 years, Pew has encouraged collaboration among its diverse community of biomedical scientists, leading to the 2017 launch of the Innovation Fund.
  • Roozbeh Kiani, M.D., Ph.D. , 2016 Pew biomedical scholar; New York University
    Nuo Li, Ph.D. , 2018 Pew biomedical scholar; Baylor College of Medicine
    Kiani and Li will explore what happens in the brain when we change our minds, a poorly understood aspect of decision-making.

Theragent Welcomes Seasoned Cell Therapy Professional Brian Newsom as New Vice President of Business Development

Retrieved on: 
Tuesday, October 24, 2023
Therapy, Business development, MD, CDMO, Invitrogen, Doctor of Philosophy, MBA, Texas Tech University, Baylor College of Medicine, Growth, Texas A&M University, Marketing, Business, Microbiology, Thermo Fisher Scientific, Life Technologies, Patient, Management

ARCADIA, Calif., Oct. 24, 2023 /PRNewswire/ -- Theragent, a comprehensive cell & gene therapy CDMO focused on advancing next-generation cancer and rare disease treatments, announced that Brian Newsom will be joining the team as their new Vice President of Business Development effective October 16th, 2023.

Key Points: 
  • ARCADIA, Calif., Oct. 24, 2023 /PRNewswire/ -- Theragent, a comprehensive cell & gene therapy CDMO focused on advancing next-generation cancer and rare disease treatments, announced that Brian Newsom will be joining the team as their new Vice President of Business Development effective October 16th, 2023.
  • Mr. Newsom will join Theragent from his latest role as Senior Director of Business Development at KBI Biopharma.
  • Mr. Newsom brings with him a three-decade mix of both technical and business development experience within the cell therapy industry.
  • "Brian's technical knowledge, business development background and CDMO experience will help drive our continued growth as we expand our presence in the cell and gene therapy market.

Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer

Retrieved on: 
Thursday, October 19, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Hyperoxaluria, Heidelberg University School of Medicine, Proctor, Endocrinology, Nephrology, Publication, Inflammation, Metabolism, Corcept Therapeutics, Baylor College of Medicine, Medicine, Amgen, Internal medicine, Neurology, Corporation, University, NDA, Safety, Therapy, Patient, BLA, Baylor University, Pharmaceutical industry, Management, Omeros

Omeros Corporation (Nasdaq: OMER) today announced that Andreas Grauer, M.D., has been named Omeros’ chief medical officer.

Key Points: 
  • Omeros Corporation (Nasdaq: OMER) today announced that Andreas Grauer, M.D., has been named Omeros’ chief medical officer.
  • In his new role, Dr. Grauer will be responsible for guiding all clinical activities globally for the company, including clinical development and operations, medical affairs, safety, and biometrics.
  • “We are very pleased to welcome Andreas to Omeros’ leadership team,” said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros.
  • He joins Omeros from Federation Bio where, as chief medical officer, he led all clinical activities with a focus on hyperoxaluria and immuno-oncology.

Dr. Huda Zoghbi Reveals New Research Into the Mechanisms Driving Rett Syndrome at the 2023 World Congress of Neurology

Retrieved on: 
Wednesday, October 18, 2023
Spectrum, Seizure, Neuron, Behavior, Human, Genetics, MD, MECP2, DSM-IV codes, Research, WCN, Dysautonomia, Baylor College of Medicine, Disorder, Rett syndrome, Neurology, Brain, Tremor, Ataxia, MECP2 duplication syndrome, Patient, Pharmaceutical industry, Medical imaging

Dr. Zoghbi's groundbreaking research not only enhances our understanding of Rett syndrome but also reveals its connection to a spectrum of neuropsychiatric phenotypes, from autism to bipolar disorders.

Key Points: 
  • Dr. Zoghbi's groundbreaking research not only enhances our understanding of Rett syndrome but also reveals its connection to a spectrum of neuropsychiatric phenotypes, from autism to bipolar disorders.
  • Her research also pinpointed the specific neurons and circuit abnormalities that mediate the various symptoms of Rett syndrome.
  • Moreover, this breakthrough research has far-reaching implications, not only for Rett syndrome but for a broader spectrum of neuropsychiatric disorders.
  • Visit wcn-neurology.com to learn more about Dr. Zoghbi and all the featured research at this year's WCN.

Dr. Huda Zoghbi Reveals New Research Into the Mechanisms Driving Rett Syndrome at the 2023 World Congress of Neurology

Retrieved on: 
Wednesday, October 18, 2023
Spectrum, Seizure, Neuron, Behavior, Human, Genetics, MD, MECP2, DSM-IV codes, Research, WCN, Dysautonomia, Baylor College of Medicine, Disorder, Rett syndrome, Neurology, Brain, Tremor, Ataxia, MECP2 duplication syndrome, Patient, Pharmaceutical industry, Medical imaging

Dr. Zoghbi's groundbreaking research not only enhances our understanding of Rett syndrome but also reveals its connection to a spectrum of neuropsychiatric phenotypes, from autism to bipolar disorders.

Key Points: 
  • Dr. Zoghbi's groundbreaking research not only enhances our understanding of Rett syndrome but also reveals its connection to a spectrum of neuropsychiatric phenotypes, from autism to bipolar disorders.
  • Her research also pinpointed the specific neurons and circuit abnormalities that mediate the various symptoms of Rett syndrome.
  • Moreover, this breakthrough research has far-reaching implications, not only for Rett syndrome but for a broader spectrum of neuropsychiatric disorders.
  • Visit wcn-neurology.com to learn more about Dr. Zoghbi and all the featured research at this year's WCN.

Diakonos Oncology Awarded FDA Fast Track Designation for Innovative Dendritic Cell Vaccine for Glioblastoma

Retrieved on: 
Tuesday, October 17, 2023
Research, FDA, Clinical Trials, Stem Cells, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Incidence, Cancer, Fast track (FDA), Food, GBM, Glioblastoma, Standard of care, Cell, Central nervous system, University, University of Arizona College of Medicine – Tucson, B cell, Baylor College of Medicine, Survival, Disease, South Texas Medical Center, MD Anderson Cancer Center, Cooper University Hospital, Viral, Neurosurgery, Immunology, Person, Texas Medical Center, Clinical trial, Immune system, Fast Track, Associate, Assistant, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Injection, Baylor University, University of Arizona College of Medicine – Phoenix, Patient, Pharmaceutical industry, Vaccine

Diakonos Oncology Corporation (“Diakonos”), a clinical stage immuno-oncology company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s unique dendritic cell vaccine, DOC1021.

Key Points: 
  • Diakonos Oncology Corporation (“Diakonos”), a clinical stage immuno-oncology company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s unique dendritic cell vaccine, DOC1021.
  • The designation was based on positive preliminary safety and efficacy data from a Phase 1 clinical trial enrolling patients with glioblastoma multiforme (GBM).
  • FDA Fast Track designation is intended to speed development and review of drugs that show early clinical promise in treating severe or life-threatening conditions.
  • This pivotal designation can help propel Diakonos closer to delivering DOC1021 to GBM patients, of which only 7% survive more than five years.

The AIM-HI Accelerator Fund Recognizes, Honors, and Congratulates Its 2023 Women’s Venture Competition Top Winners

Retrieved on: 
Monday, October 16, 2023
Research, Women, Clinical Trials, Biotechnology, Health, Consumer, Other Science, Science, Oncology, T-cell acute lymphoblastic leukemia, MBA, TCL, Hope, Press club, T-ALL, RNA, United Nations Foundation, Distinction, Prize, National Foundation for Cancer Research, Baylor College of Medicine, CTC, Cancer, Winners, Therapy, MGD, Environment, Survivor, First Prize, Woman, Baylor University, Patient, National Press Club (United States), T-cell lymphoma, Pharmaceutical industry, Vaccine

Blue-ribbon judge committee members selected them from a pool of 71 female-led, early-stage oncology companies across 15 countries.

Key Points: 
  • Blue-ribbon judge committee members selected them from a pool of 71 female-led, early-stage oncology companies across 15 countries.
  • The Phase 1 clinical trial has demonstrated strong efficacy and safety signals, with multiple long-term survivors in remission years after treatment.
  • This recognition from AIM-HI is an acknowledgment of our hard work and an affirmation of our technology platform,” said Dr. Hein.
  • In addition to the first and second-place winners, Delee was selected as The 2023 People’s Choice for “Best Pitch” by a public audience voting for their favorite pitch presentation during the 2023 Women’s Venture Competition selection process.

Promontory Therapeutics Presents Data on the Molecular Effects of PT-112 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Saturday, October 14, 2023
European Organisation for Research and Treatment of Cancer, Treatment, Research and development, RNA, AACR, International Conference on Defects in Semiconductors, Baylor College of Medicine, EORTC, National Cancer Institute, Non-small-cell lung cancer, American Association for Cancer Research, Therapy, NCI, Gene, Prostate cancer, Prostate, Small RNA, Baylor University, Promontory, Conference, ICD, Pharmaceutical industry, Platinum, Vaccine, Doctor of Philosophy, Cancer, Research

NEW YORK, Oct. 14, 2023 /PRNewswire/ -- Promontory Therapeutics Inc., a clinical stage biotech company advancing immunogenic small molecule approaches in oncology, today presented data on its lead therapeutic candidate PT-112, detailing its early molecular effects that culminate in immunogenic cancer cell death (ICD). The presentation was made at the American Association for Cancer Research (AACR) – National Cancer Institute (NCI) – European Organisation for Research and Treatment of Cancer (EORTC) International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023 in Boston.

Key Points: 
  • The presentation was made at the American Association for Cancer Research (AACR) – National Cancer Institute (NCI) – European Organisation for Research and Treatment of Cancer (EORTC) International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023 in Boston.
  • Researchers also conducted nascent RNA sequencing in human cancer cells (non-small cell lung, prostate and renal cell carcinoma) following one and six hours of PT-112 treatment.
  • "While further validation of these findings is ongoing, this work deepens our understanding of PT-112's specific molecular effects.
  • PT-112 rapidly causes ribosomal biogenesis (RiBi) inhibition and nucleolar stress, likely driving previously observed PT-112-induced cancer organelle stresses and ICD.